chronic neurological disorder
Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA
Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma
Teva submits FDA application for paediatric Tourette syndrome therapy
Ecopipam could become the first new FDA-approved treatment for paediatric Tourette syndrome in over ten years
Roche’s Enspryng given FDA Priority Review as thyroid eye disease treatment
This is the first and only at-home subcutaneous treatment option for this disease
AbbVie to acquire Apogee Therapeutics in $10.9bn deal
The acquisition includes clinical-stage candidates for atopic dermatitis and asthma
Regeneron’s New Drug Application for cemdisiran accepted for review by FDA and EMA
Globally, around 150 to 200 out of every million people have myasthenia gravis
Roche’s Tecentriq gets FDA Priority Review for specific stage 3 colon cancer
Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years
Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis
This new option for patients allows for as few as six maintenance injections per year
FDA gives Rare Paediatric Disease designation to Satellite Bio for urea cycle disorders
The mortality rates of UCDs exceeds 25%, with no curative treatment available for newborns
Sumitomo Pharma’s stem cell therapy for Parkinson’s given limited approval in Japan
The company has been given manufacturing and marketing authorisation for the therapy
Allergan Aesthetics launches Skin Quality Index for aesthetic consultations
Spanning four dimensions of skin health, the framework introduces 15 terms and definitions
Annovis partners with NeuroRPM on new AI platform to track Parkinson’s symptoms
The platform will passively collect data to understand treatment responses in everyday life
BMS’ Opdivo gets expanded FDA and EU approval for Hodgkin lymphoma
This type of cancer is the most common one diagnosed in teenagers